Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Princeton, US
Size (employees)
90 (est)
Advaxis was founded in 2002 and is headquartered in Princeton, US

Key People at Advaxis

Daniel J. O'Connor

Daniel J. O'Connor

President, Chief Executive Officer and Director
Thomas A. Moore

Thomas A. Moore

Chairman / CEO
Thomas J. McKearn

Thomas J. McKearn

Roni A. Appel

Roni A. Appel

Richard Berman

Richard Berman

Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has office in Princeton
Princeton, US

Advaxis Metrics

Advaxis Summary

Market capitalization

$321.6 m

Closing share price

Advaxis's current market capitalization is $321.6 m.

Advaxis Financials

Advaxis's revenue is $4 m in FY, 2016
FY, 2013FY, 2014FY, 2015FY, 2016


$1.9 m$1 m$4 m

Revenue growth, %


Operating expense total

$71.4 m$20.5 m$48.7 m


($69.5 m)($19.5 m)($48.7 m)

Net Income

($67.5 m)($16.5 m)($47 m)($73.6 m)

Operating cash flow

$20.6 m($2.9 m)$49 m

Advaxis Market Value History

We estimate that Advaxis's current employees are approximately 27% female and 73% male.

Advaxis Online Presence

Advaxis Company Life

You may also be interested in